1. Generics Bulletin
  2. >>Business

Glenmark Divests API Company, Setting Out On Distinct Journeys

 
• By Anju Ghangurde

Glenmark Pharmaceuticals has divested its API arm to the Nirma group for over $681m, a move that will deleverage the drug maker’s balance sheet as it seeks to evolve into an “innovative/brand led organization.”

Glenmark sheds API business • Source: Shutterstock

Glenmark Pharmaceuticals Limited has divested its active pharmaceutical ingredients (API) business to the diversified Indian group Nirma Limited for INR56.51bn ($681m), ending long-running speculation of an imminent deal.

In a late evening announcement on 21 September, Glenmark said it had struck a definitive agreement with Nirma to sell...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Sun Strikes Further US Price-Fixing Settlement For $200m

 
• By Dave Wallace

The latest development in the long-running US generic price-fixing saga has seen Sun Pharma agree a $200m settlement in connection with an end purchaser action in Pennsylvania.

FDA Inspection Finds Leaks and Mold at Sun Pharma Halol Facility

 
• By Dean Rudge

Sun Pharma is facing renewed scrutiny after a scathing US Food and Drug Administration inspection at its Halol facility in Gujarat painted a grim picture of a facility operating in disregard of basic pharmaceutical safety standards.

Irish Ruling Gives Go-Ahead For Endo-Mallinckrodt Merger

 
• By Dave Wallace

A ruling from Ireland’s High Court has cleared the way for Endo and Mallinckrodt to consummate their merger in early August.

Cipla CEO On Tariff Threat: ‘We Have One Of The Most Well Diversified Models’

 
• By Anju Ghangurde

Cipla's leadership fields shareholder queries on the specter of US tariffs and also outlines how the firm is nurturing the business for the future in areas like mRNA and point-of-care diagnostics, while building on its strength in the respiratory space.

More from Generics Bulletin

‘Europe Has To Make Up Its Mind’ – Medicines For Europe’s Sieger On The Path Ahead

 
• By Dave Wallace

At an eventful time for the European generics and biosimilars industry, Medicines for Europe interim president and Polpharma CEO Markus Sieger talks about what the European healthcare sector needs and what the off-patent sector can deliver.

FDA Inspection Finds Leaks and Mold at Sun Pharma Halol Facility

 
• By Dean Rudge

Sun Pharma is facing renewed scrutiny after a scathing US Food and Drug Administration inspection at its Halol facility in Gujarat painted a grim picture of a facility operating in disregard of basic pharmaceutical safety standards.

US Federal Circuit Clears Path for MSN to Market Entresto Generic

 
• By Dean Rudge

Novartis has failed to secure a court order to stop MSN from launching a generic Entresto, and has also seen an earlier temporary ban lifted, potentially opening the market to competition before a final decision on a US patent dispute.